Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1 Central Nervous System Neoplasms 1

Interventions

rozanolixizumab 11 efgartigimod alfa 10 zilucoplan 8 Prednisone 8 Cyclophosphamide 8 ravulizumab 7 Rituximab 7 Pyridostigmine Bromide 7 telitacicept 6 fludarabine 6 Tacrolimus 6 Mycophenolic Acid 6 eculizumab 5 Immunoglobulins, Intravenous 5 Hizentra 4 Azathioprine 4 Steroids 3 HBM9161 3 Data Collection 3 Amifampridine 3 thymoglobulin 2 inebilizumab 2 Thymectomy 2 Prednisolone 2 Methylprednisolone 2 Methotrexate 2 Exercise 2 Diagnostic Self Evaluation 2 Blood Specimen Collection 2 tofacitinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × Oxaloacetic Acid × Clear all

NCT04965987 2025-07-11

Oxaloacetate in Myasthenia Gravis

University of Kansas Medical Center

Phase 1 Withdrawn

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡